Evolus Inc (EOLS) Receives $31.40 Consensus Target Price from Analysts

Evolus Inc (NASDAQ:EOLS) has earned an average rating of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $31.40.

A number of equities analysts have commented on the company. Zacks Investment Research downgraded Evolus from a “hold” rating to a “sell” rating in a research note on Tuesday, February 5th. Stifel Nicolaus initiated coverage on Evolus in a report on Monday, January 28th. They set a “buy” rating and a $27.00 target price on the stock.

In other Evolus news, Director Vikram Malik purchased 7,800 shares of the company’s stock in a transaction that occurred on Monday, December 17th. The stock was purchased at an average price of $13.04 per share, with a total value of $101,712.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Corp Alphaeon sold 573,888 shares of the stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $14.00, for a total transaction of $8,034,432.00. The disclosure for this sale can be found here. In the last three months, insiders have acquired 17,147 shares of company stock valued at $228,880.

Institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN grew its stake in shares of Evolus by 860.3% during the third quarter. Wells Fargo & Company MN now owns 5,944 shares of the company’s stock valued at $110,000 after purchasing an additional 5,325 shares during the last quarter. IFP Advisors Inc raised its holdings in Evolus by 239.6% in the fourth quarter. IFP Advisors Inc now owns 8,490 shares of the company’s stock worth $101,000 after purchasing an additional 5,990 shares during the period. Schwab Charles Investment Management Inc. acquired a new stake in Evolus in the second quarter worth $258,000. Rhumbline Advisers acquired a new stake in shares of Evolus during the fourth quarter worth $129,000. Finally, Raymond James & Associates acquired a new stake in shares of Evolus during the second quarter worth $327,000. 24.91% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:EOLS traded down $0.56 during mid-day trading on Wednesday, reaching $26.00. The stock had a trading volume of 1,492,600 shares, compared to its average volume of 1,461,977. The company has a market capitalization of $776.25 million and a price-to-earnings ratio of -96.30. Evolus has a 1-year low of $6.75 and a 1-year high of $39.50.

About Evolus

Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

Featured Article: What is a Roth IRA?

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit